Teva offloads two more ANDAs to satisfy Allergan Generics deal

20 June 2016

India’s Zydus Cadila has added to its US portfolio by buying two new Abbreviated New Drug Applications (ANDAs) from Israeli generics giant Teva Pharmaceutical Industries (NYSE: TEVA) in an undisclosed transaction.

These are being divested by Teva as a pre-condition of its $40.5 billion purchase of the generics business of Ireland-incorporated Allergan (NYSE: AGN). Conditions state that the company must offload certain assets to avoid the merged entity breaching competition requirements.

Zydus Worldwide DMCC, a wholly-owned subsidiary of the Ahmedabad-based company, has bought the ANDAs in a transaction to be financed through the group's internal accruals.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK